Journal
INTERNATIONAL JOURNAL OF CANCER
Volume 134, Issue 6, Pages 1379-1388Publisher
WILEY
DOI: 10.1002/ijc.28473
Keywords
S100A7; hnRNPK; PTMA; 14-3-3; 14-3-3 sigma; oral cancer; biomarker; immunohistochemistry; dysplasia; progression; transformation
Categories
Funding
- Canadian Institutes of Health Research (CIHR)
- International Science and Technology Partnerships (ISTP) Canada-Department of Biotechnology (DBT), India
Ask authors/readers for more resources
Early detection of oral lesions (OLs) at high risk of cancer development is of utmost importance for intervention. There is an urgent unmet clinical need for biomarkers that allow identification of high-risk OLs. Recently, we identified and verified a panel of five candidate protein biomarkers namely S100A7, prothymosin alpha, 14-3-3, 14-3-3 sigma and heterogeneous nuclear ribonucleoprotein K using proteomics to distinguish OLs with dysplasia and oral cancers from normal oral tissues. The objective of our study was to evaluate the potential of these candidate protein biomarkers for identification of oral dysplastic lesions at high risk of cancer development. Using immunohistochemistry, we analyzed expressions of these five candidate protein biomarkers in 110 patients with biopsy-proven oral dysplasia and known clinical outcome and determined their correlations with p16 expression and HPV 16/18 status. Kaplan-Meier survival analysis showed reduced oral cancer-free survival (OCFS) of 68.6 months (p = 0.007) in patients showing cytoplasmic S100A7 overexpression when compared to patients with weak or no S100A7 immunostaining in cytoplasm (mean OCFS = 122.8 months). Multivariate Cox regression analysis revealed cytoplasmic S100A7 overexpression as the most significant candidate marker associated with cancer development in dysplastic lesions (p = 0.041, hazard ratio = 2.36). In conclusion, our study suggested the potential of S100A7 overexpression in identifying OLs with dysplasia at high risk of cancer development. What's new? Identification of oral lesions with dysplasia at high risk of malignant transformation remains a major clinical challenge, and is of utmost importance for identifying patients who would benefit from early intervention. Currently, there are no biomarkers that are being routinely used in clinics to predict high-risk lesions. Here, the authors evaluated the potential of five candidate protein biomarkers and correlated their expression with p16 and HPV 16/18 to identify oral lesions with dysplasia at high risk of cancer development. S100A7 overexpression demonstrated the potential to serve as a useful marker for estimating the risk of oral dysplasia progressing to cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available